Riskpilot← Back to searchSign inGet full accessMedlunger AB
ABIn liquidationOrg 5592122732Medical specialists activities · NACE 8622Est. 20191 employees
Revenue 2024
SEK 202K
-65% vs 2023
EBITDA margin
72.5%
-61% vs 2023
Equity ratio
72.3%
Financial strength
Net profit 2024
SEK 119K
-64% vs 2023
| Revenue | SEK 202K | -65% |
| EBITDA | SEK 147K | -61% |
| Net profit | SEK 119K | -64% |
| Total assets | SEK 347K | -55% |
| Equity | SEK 251K | -60% |
| Employees | 1 | — |
Legal name
Medlunger AB
Org number
5592122732
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
11 juli 2019
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-06-30
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget skall bedriva vård och omsorg, medicinska tjänster och konsultationer, läkarbemanning inom sluten och öppen vård, medicinsk vård och hembesök, seminarier, konferenser, utbildningar, handel med värdepapper, förvaltning av fastigheter och därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 676 | 632 | 344 | 572 | 202 |
| Staff expenses | — | — | −449 | −148 | −15 |
| EBITDA | 439 | 105 | −174 | 373 | 147 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 439 | 105 | −174 | 373 | 147 |
| Net financials | — | — | −2 | 0 | 3 |
| Profit before tax | 329 | 77 | −65 | 401 | 150 |
| Tax | −71 | −18 | — | −72 | −30 |
| Net profit | 258 | 59 | −65 | 330 | 119 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 742 | 871 | 482 | 771 | 347 |
| Equity | 308 | 368 | 302 | 632 | 251 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 324 | 366 | 151 | 139 | 96 |
| Total debt | 324 | 366 | 151 | 139 | 96 |
EBITDA margin
72.5%
This company
15.8%
Market median
+359% vs market
20202024
Equity ratio
72.3%
This company
38.2%
Market median
+89% vs market
20202024
Return on equity
47.5%
This company
18.4%
Market median
+158% vs market
20202024
Net profit margin
59.0%
This company
8.1%
Market median
+628% vs market
20202024
Asset turnover
0.58×
This company
1.12×
Market median
-48% vs market
20202024
Debt / equity
0.38×
This company
0.62×
Market median
+39% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-07-01 – 2020-06-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PM Liquidator | Liquidator | 2025 |
| Former (1) | ||
KA Authorized Recipient of Service | Authorized Recipient of Service | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Board of Directors | 2022 – 2025 | |
| Deputy Board Member | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Medlunger AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Martin Rosengren | Liquidator | 0 companies |
| Kirk Allen Scott | Authorized Recipient of Service | 0 companies |
| Elke Peters | Board of Directors | 0 companies |
| Julius Vormelker | Deputy Board Member | 0 companies |